NCT04978493: A reported trial by Boehringer Ingelheim
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04978493 |
|---|---|
| Title | A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 2, 2021 |
| Completion date | July 8, 2024 |
| Required reporting date | July 8, 2025, midnight |
| Actual reporting date | July 7, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |